Editas Medicine (EDIT) Stock Price, Quote & News

Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in No...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 401 9000

Website: www.editasmedicine.com

Address:

11 Hurley Street, Cambridge, United States

alexx013 Oct. 27 at 3:12 PM

$EDIT bought @ 3.2

0 · Reply

Ebrice73 Oct. 27 at 2:59 PM

$EDIT

0 · Reply

GoBio2022 Oct. 27 at 2:31 PM

$EDIT shorts getting down and dirty

0 · Reply

JSInvestments Oct. 27 at 2:17 PM

$EDIT shaping up to take a bigger beating the NTLA - makes complete sense.

0 · Reply

Robert_Dempster Oct. 27 at 2:16 PM

$EDIT buying opportunity here🐂

0 · Reply

Ducmanallja Oct. 27 at 1:52 PM

$EDIT WTF?

0 · Reply

Whoami1989 Oct. 27 at 1:42 PM

$EDIT f garbage

0 · Reply

harryvanluik Oct. 27 at 1:39 PM

$EDIT NTLA already recovering. One older person with high BMI showed some bilirubin increase. NTLA decide to first take a look at this...so they paused the test themselves. No problem for EDIT...time to step in is NOW!

0 · Reply

Whoami1989 Oct. 27 at 1:38 PM

$EDIT where are cheerleaders? i need you now more than ever

0 · Reply

0x126 Oct. 27 at 12:52 PM

$EDIT $NTLA tanking 45% taking us down 8%? Anyone has information? No time to listen

1 · Reply

Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?

Oct 9, 2025, 11:01 AM EDT - 18 days ago

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Oct 6, 2025, 9:00 AM EDT - 21 days ago

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Sep 2, 2025, 11:14 AM EDT - 7 weeks ago

Editas Medicine, Inc. - Special Call

Sep 2, 2025, 7:00 AM EDT - 7 weeks ago

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Aug 28, 2025, 4:01 PM EDT - 2 months ago

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Aug 27, 2025, 9:00 AM EDT - 2 months ago

Editas Medicine to Participate in Upcoming Investor Conferences

Aug 12, 2025, 4:01 PM EDT - 2 months ago

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Jun 12, 2025, 2:01 AM EDT - 4 months ago

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

May 20, 2025, 5:47 AM EDT - 5 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT NTLA VANI VERV

May 14, 2025, 2:17 PM EDT - 5 months ago

Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 9:31 AM EDT - 5 months ago

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

May 14, 2025, 7:01 AM EDT - 5 months ago

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025, 7:01 AM EDT - 5 months ago

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

May 12, 2025, 4:30 PM EDT - 5 months ago

Editas Medicine Announces First Quarter 2025 Results and Business Updates

May 12, 2025, 4:01 PM EDT - 5 months ago

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

May 5, 2025, 4:01 PM EDT - 6 months ago

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Apr 28, 2025, 4:31 PM EDT - 6 months ago

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Mar 20, 2025, 4:01 PM EDT - 7 months ago

Editas Medicine Announces Chief Financial Officer Transition

Mar 11, 2025, 4:07 PM EDT - 8 months ago

Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)

Mar 10, 2025, 12:19 PM EDT - 8 months ago

Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)

Mar 5, 2025, 4:05 PM EST - 8 months ago

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Mar 3, 2025, 5:01 PM EST - 8 months ago

Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript

Feb 24, 2025, 9:00 AM EST - 8 months ago

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Jan 17, 2025, 12:20 PM EST - 10 months ago

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

NTLA

Jan 15, 2025, 4:35 PM EST - 10 months ago

Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Jan 13, 2025, 9:00 AM EST - 10 months ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Jan 6, 2025, 9:00 AM EST - 10 months ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 6:44 AM EST - 11 months ago

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Dec 12, 2024, 6:03 PM EST - 11 months ago

Editas to reduce about 65% of its workforce over the next six months

Dec 12, 2024, 4:00 PM EST - 11 months ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec 9, 2024, 12:00 PM EST - 11 months ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Dec 3, 2024, 10:52 PM EST - 11 months ago

Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)

Nov 25, 2024, 12:59 PM EST - 11 months ago

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

Nov 19, 2024, 7:53 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)

Nov 4, 2024, 7:30 AM EST - 1 year ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Oct 22, 2024, 11:45 AM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript

Oct 21, 2024, 4:30 PM EDT - 1 year ago

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Oct 18, 2024, 4:01 PM EDT - 1 year ago

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Oct 7, 2024, 3:33 PM EDT - 1 year ago

Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations

Oct 6, 2024, 2:00 PM EDT - 1 year ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY CRSP EXAS NTLA

Oct 3, 2024, 6:00 PM EDT - 1 year ago

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Oct 1, 2024, 7:53 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Chardan's 8th Annual Genetic Medicines Conference (Transcript)

Sep 25, 2024, 11:46 AM EDT - 1 year ago

Editas Medicine: A Risk/Reward Worth Considering

Sep 17, 2024, 5:26 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)

Sep 5, 2024, 11:19 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript)

Sep 4, 2024, 7:17 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Aug 7, 2024, 12:03 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

alexx013 Oct. 27 at 3:12 PM

$EDIT bought @ 3.2

0 · Reply

Ebrice73 Oct. 27 at 2:59 PM

$EDIT

0 · Reply

GoBio2022 Oct. 27 at 2:31 PM

$EDIT shorts getting down and dirty

0 · Reply

JSInvestments Oct. 27 at 2:17 PM

$EDIT shaping up to take a bigger beating the NTLA - makes complete sense.

0 · Reply

Robert_Dempster Oct. 27 at 2:16 PM

$EDIT buying opportunity here🐂

0 · Reply

Ducmanallja Oct. 27 at 1:52 PM

$EDIT WTF?

0 · Reply

Whoami1989 Oct. 27 at 1:42 PM

$EDIT f garbage

0 · Reply

harryvanluik Oct. 27 at 1:39 PM

0 · Reply

Whoami1989 Oct. 27 at 1:38 PM

$EDIT where are cheerleaders? i need you now more than ever

0 · Reply

0x126 Oct. 27 at 12:52 PM

$EDIT $NTLA tanking 45% taking us down 8%? Anyone has information? No time to listen

1 · Reply

trendtrader6 Oct. 26 at 3:30 PM

$ARKG weekly. at the top of the volume resistance. over 34 weekly close should confirm break out. $CRSP $EDIT

0 · Reply

WallStreetBuyDip Oct. 25 at 12:06 PM

$EDIT Trading in a wide range recently, bouncing between $3.57 and $4.14. Current price at $3.72 with average volume around 2.8 million. Volume spikes seen with price movements.

1 · Reply

0x126 Oct. 24 at 4:47 PM

$EDIT Friday green is nice after this week's senseless drop. Hope it stays at 3-4% +

0 · Reply

Awiz2 Oct. 24 at 1:10 PM

$EDIT The run back up begins!!!!

0 · Reply

Robert_Dempster Oct. 24 at 12:34 PM

$EDIT downside surprise we're off to the races📈🐂🐂

0 · Reply

Robert_Dempster Oct. 24 at 11:29 AM

$EDIT inflation data cpi 8:30 eastern should fuel The rally📈🐂

0 · Reply

Ebrice73 Oct. 23 at 9:26 PM

$EDIT and we go

0 · Reply

Realy Oct. 23 at 3:20 PM

$XBI wouldn’t mind it taking 3 times to break above 111…☕️ $LABU $LABD $EDIT

0 · Reply

0x126 Oct. 23 at 10:58 AM

$EDIT would be great to stop jumping 8-10% a day and interaday

0 · Reply

DoctrBenway Oct. 22 at 4:03 PM

$EDIT Added @ 3.53

1 · Reply

0x126 Oct. 22 at 3:59 PM

$EDIT if anyone is in doubt about why we are down. Some algos, fonds and bots sell off bio sector. Next will be jump by 15-20% up due to US central bank lowing interest rates. R&D always goes up with cheap money

0 · Reply

0x126 Oct. 22 at 3:57 PM

$EDIT need cash to buy more. FML

1 · Reply

Market Cap	334.50M
Revenue (ttm)	32.31M
Net Income (ttm)	-237.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-733.80%
Debt to Equity Ratio	0.00

Volume	1,626,500
Avg Vol	2,385,364
Day's Range	N/A - N/A
Shares Out	89.92M
Stochastic %K	40%
Beta	2.18
Analysts	Sell
Price Target	$3.67